Improving the monitoring and care of patients with familial hypercholesterolemia

Journal of the American College of Cardiology

Volumn 67, Issue 11, 2016, Pages 1286-1288

  Hegele, Robert A ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

atherosclerosis; genetics; prevention; registries

Indexed keywords

ALIROCUMAB; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ATORVASTATIN; HYPOCHOLESTEROLEMIC AGENT; ROSUVASTATIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; FAMILIAL HYPERCHOLESTEROLEMIA; GENE; GENE FREQUENCY; GENE MUTATION; HETEROZYGOSITY; HUMAN; LDLR GENE; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT OUTCOME; BLOOD; FEMALE; HYPERLIPOPROTEINEMIA TYPE II; MALE; REGISTER;

ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; CHOLESTEROL, LDL; EZETIMIBE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; REGISTRIES; ROSUVASTATIN CALCIUM;

EID: 84962791762     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.01.041     Document Type: Editorial

References (16)

1. B.G. Nordestgaard, M.J. Chapman, S.E. Humphries, and et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society Eur Heart J 34 2013 3478 3490
2. S.S. Gidding, M. Ann Champagne, S.D. de Ferranti, and et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association Circulation 132 2015 2167 2192
3. J. Genest, R.A. Hegele, J. Bergeron, and et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia Can J Cardiol 30 2014 1471 1481
4. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group BMJ 303 1991 893 896
5. J. Versmissen, D.M. Oosterveer, M. Yazdanpanah, and et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study BMJ 337 2008 a2423
6. K.K. Ray, J.J. Kastelein, S.M. Boekholdt, and et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011 Eur Heart J 35 2014 960 968
7. T.J. Anderson, J. Grégoire, R.A. Hegele, and et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 29 2013 151 167
8. R. Huijgen, I. Kindt, S.B. Verhoeven, and et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal PLoS One 5 2010 e9220
9. L. Perez de Isla, R. Alsonso, G.F. Watts, and et al. Attainment of LDL cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up J Am Coll Cardiol 67 2016 1278 1285
10. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
11. R.A. Hegele, S.S. Gidding, H.N. Ginsberg, and et al. Nonstatin low-density lipoprotein-lowering therapy and cardiovascular risk reduction-statement from ATVB Council Arterioscler Thromb Vasc Biol 35 2015 2269 2280
12. E.C. O'Brien, M.T. Roe, E.S. Fraulo, and et al. Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry Am Heart J 167 2014 342 349
13. J.J. Kastelein, H.N. Ginsberg, G. Langslet, and et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia Eur Heart J 36 2015 2996 3003
14. F.J. Raal, E.A. Stein, R. Dufour, and et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Lancet 385 2015 331 340
15. M.J. Lipinski, U. Benedetto, R.O. Escarcega, and et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis Eur Heart J 37 2016 536 545
16. J.A. Tice, D.S. Kazi, and S.D. Pearson Proprotein convertase subtilisin/kexin type 9 (PSCK9) inhibitors for treatment of high cholesterol levels: effectiveness and value JAMA Intern Med 176 2016 107 108